Y Umemura, H Ogura, K Takuma, S Fujishima… - International Journal of …, 2021 - Elsevier
Background There is no one-size-fits-all empiric antimicrobial therapy for sepsis because the pathogens vary according to the site of infection and have changed over time. Therefore …
AMM van Deursen, MA van Houten… - Clinical Infectious …, 2017 - academic.oup.com
Background In the randomized controlled Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA), the efficacy of the 13-valent pneumococcal conjugate vaccine …
Introduction Community-acquired pneumonia (CAP) is a common infection associated with high morbimortality and a highly deleterious impact on patients' quality of life and …
SI Pelton, KM Shea, RA Farkouh, DR Strutton… - BMC infectious …, 2015 - Springer
Background The objective of this study is to evaluate rates of all-cause pneumonia among “at-risk” and “high-risk” children and adults in Germany—in comparison with age-stratified …
AMM van Deursen, MA van Houten… - Clinical Infectious …, 2018 - academic.oup.com
Background The impact of pneumococcal conjugate vaccination on the prevalence of nasopharyngeal carriage with pneumococci and other bacteria in adults is unknown. The …
RA Corrêa, AN Costa, F Lundgren… - Jornal Brasileiro de …, 2018 - SciELO Brasil
RESUMO A pneumonia adquirida na comunidade (PAC) constitui a principal causa de morte no mundo. Apesar da vasta microbiota respiratória, o Streptococcus pneumoniae …
В обзоре рассматриваются клинические и эпидемиологические связи между COVID-19 и пневмониями. При этом обсуждаются как общие закономерности, связывающие …
RA Corrêa, AN Costa, F Lundgren… - Jornal Brasileiro de …, 2018 - SciELO Brasil
Community-acquired pneumonia (CAP) is the leading cause of death worldwide. Despite the vast diversity of respiratory microbiota, Streptococcus pneumoniae remains the most …
A Janssens, B Vaes, C Abels, J Crèvecoeur… - BMC Public Health, 2023 - Springer
Abstract Background Since 2014, Belgium's Superior Health Council has recommended pneumococcal vaccination for adults aged 19–85 years at increased risk for pneumococcal …